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Abstract
EBV-encoded microRNAs (miRNAs) have been identified and their functions are being studied. The
expression pattern of these miRNAs in clinical samples of EBV-associated non–Hodgkin’s
lymphomas is unknown. We analyzed five primary “endemic” pediatric Burkitt’s lymphomas (BL),
two acquired immunodeficiency syndrome (AIDS)-related type I latency BL lines, a type III latency
line, three EBV+ primary effusion lymphomas (PEL), and three AIDS-related diffuse large B-cell
lymphomas (DLBCL) for expression of EBV-encoded miRNAs. A markedly elevated expression of
miRNA BHRF1-3 in type III relative to its parental type I BL line was found. Primary unmanipulated
type I BLs and EBV+ PELs expressed high levels of BART2 miRNA, whereas DLBCLs expressed
both BART2 and BHRF1-3 species. BHRF1-3 miRNA expression inversely correlated with levels
of a putative cellular target, the IFN-inducible T-cell attracting chemokine CXCL-11/I-TAC, and
suppression of this factor was reversed by transfection of an antisense oligo to the EBV miRNA
BHRF1-3. EBV-encoded miRNAs are expressed in primary lymphomas classically linked to the
virus and are associated with the viral latency status. Targeted suppression of CXCL-11/I-TAC by a
viral-encoded miRNA may serve as an immunomodulatory mechanism in these tumors.
Introduction
MicroRNAs (miRNA) are small noncoding RNAs of ~22 nucleotides processed from primary
transcripts (pri-miRNAs) to short stem-loop RNA precursors of ~60 nucleotides (pre-miRNAs)
and finally to functional miRNAs. miRNAs regulate gene expression by base pairing with the
3′-untranslated region (UTR) of their target mRNAs and repress target gene translation or
induce target mRNA degradation. miRNAs have important regulatory functions as indicated
by their gene specificity and modulation (1–3). The absence of miRNAs in all unicellular
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organisms studied thus far makes a case for their role in highly specialized cell functions (4,
5).
A growing body of data indicates that viruses exploit the miRNA machinery to modulate and/
or subvert virus-host cell interactions (6–10). Pfeffer et al. (7) initially identified five EBV-
encoded miRNAs from the B95-8 EBV laboratory strain. The EBV-encoded BHRF1 miRNAs
cluster map to the 5′-UTR (BHRF1-1) and 3′-UTR (BHRF1-2 and BHRF1-3) of the BHRF1
(BamHI fragment H rightward open reading frame 1) gene, whereas the BART miRNAs
(BART1 and BART2) cluster map to intronic regions of the BART (BamHI-A region rightward
transcript) gene. Cai et al. (8) identified additional BART miRNAs from an EBV-infected
primary effusion lymphoma (PEL) cell line, and Grundhoff et al. (10) identified additional
EBV miRNAs in the BART and BHRF1 region, bringing the total to 22 clustered, EBV-encoded
miRNAs. The conservation of miRNAs in the lymphocryptoviruses indicates their importance
in the viral life cycle, and the elucidation of their function is ongoing albeit incompletely
understood.
The typical outcome of EBV infection is viral latency, which may eventually result in
transformation (11,12). Latency patterns have been defined based on EBV gene expression in
distinct tumor subtypes. Primary Burkitt’s lymphomas (BL) generally show the type I pattern
of latency, whereas posttransplant lymphoproliferative disease, immunoblastic lymphomas
[including some acquired immunodeficiency syndrome (AIDS)-related lymphomas], as well
as in vitro–transformed lymphoblastoid cell lines (LCL) adopt the latency type III pattern of
gene expression (12). Latency variation is consistent with the hypothesis that the more
restricted the viral gene expression, the easier it is for the virally infected cell to escape immune
surveillance. In the absence of immunologic constraints, such as in vitro, primary BL cell
cultures tend to drift from the classic type I latency to a type III lymphoblastoid phenotype
(11,12). Prior studies have focused exclusively on long-term culture propagated cell lines.
These can accumulate mutations in viral miRNA loci, such as exemplified by B95-8 (7), or
the host genome, which may alter miRNA transcription, processing, or stability. Here, we
extend these studies by analyzing viral miRNA levels by two independent methods, RNase
protection assay (RPA) and a novel quantitative PCR (QPCR) method, in early-passage
primary BL cultures, a lymphoblastoid derivative of BL, and a wide variety of unmanipulated
primary EBV-related lymphomas. We show that EBV-encoded BHRF1-3 miRNA levels are
markedly elevated in the type III latency cell line and for the first time in primary EBV-
associated AIDS-related diffuse large B-cell lymphomas (DLBCL). Primary BLs and PELs
expressed high levels of BART2 but not BHRF1-3 miRNA. We further show that BHRF1-3
miRNA represses the expression of the IFN-inducible T-cell attracting chemokine, CXCL-11/
I-TAC, a putative cellular target of BHRF1-3 miRNA. This targeted suppression of CXCL-11/
I-TAC by BHRF1-3 miRNA may serve as an immunomodulatory mechanism in EBV-related
lymphomas.
Materials and Methods
Cell culture, collection, and histologic confirmation of primary tumors
This study was approved by the University of Miami and the Federal University of Bahia
Institutional Review Boards. Informed consent was obtained from patients or their guardians
before obtaining clinical samples, and only tissue deemed unnecessary for pathologic diagnosis
was used. BL-5 and BL-8 cells are primary cultures derived from patients with AIDS-related
EBV+ BL. The tumors carry the typical t8:14 c-MYC translocation (13). A lymphoblastoid
derivative (BL-5R) was obtained after serially passaging BL-5 cells over a 4- to 5-week period.
BC-1 and JSC-1 are PEL lines that are dually infected with human herpes virus type 8 (HHV-8)
and EBV (14). Cells were cultured in RPMI 1640 (Life Technologies) supplemented with 10%
fetal bovine serum, 1% penicillin and streptomycin, 1% glutamine, and 1 mmol/L sodium
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pyruvate at 37°C in a 5% CO2-humidified atmosphere. The PEL cell lines were maintained in
the same medium with the addition of 1 unit/mL human interleukin-6.
Primary EBV+ lymphomas were obtained from an area where an extremely high (~90%)
association between EBV and pediatric Burkitt’s type histology has been reported (15,16).
Pediatric BLs (BL-1, BL-2, BL-3, BL-4, and BL-6) and EBV+ DLBCLs from AIDS patients
(DLBCL-1, DLBCL-2, and DLBCL-3) were obtained from the residual tumor of patient
biopsies. A primary PEL specimen (PELmo1) coinfected with EBV and HHV-8 was obtained
from residual material from a diagnostic procedure. The EBV− primary DLBCL (DLBCL-4),
the BJAB line, and the EBV− PEL lines BCBL-1 and BC-3 served as controls. Classification
of lymphomas was made by an experienced hematopathologist (I.A.) and association with EBV
was determined by eber staining. RNA was prepared as described below from tumors before
any culture step or other manipulation.
Total RNA and miRNA extraction
RNA was extracted with the RNeasy kit (Qiagen, Inc.) for analyses of cellular and EBV RNAs
by reverse transcription-PCR (RT-PCR). For RNase protection analysis of miRNAs, total RNA
and miRNA-enriched fractions were prepared with the mirVana miRNA extraction kit
(Ambion, Inc.). For real-time QPCR analysis, total RNA was isolated by RNAzol (Sigma, Inc.)
and residual DNA was removed using Turbo DNA-free (Ambion). RNA was quantitated by
UV absorption at 260 nm/280 nm using an Ultrospec 1000 machine (Pharmacia Biotech, Inc.).
PCR analyses
cDNA was synthesized using Moloney murine leukemia virus reverse transcriptase (Promega,
Inc.) according to the manufacturer’s instructions. cDNA (2 μL) was PCR amplified with gene-
specific primers as previously described (17). Real-time QPCR primers for BART1, BART2,
and BHRF1-3 are shown in Supplementary Table S1. Reverse transcription, real-time QPCR,
and data analysis were conducted following our established procedures (17,18). The final PCR
contained 7.5 μL primer mix (final concentration, 166 nmol/L), 15 μL of 2× SYBR PCR mix
(Applied Biosystems), and a 7.5 μL sample. To guard against contamination and handling
errors, all real-time QPCRs were assembled in a segregated clean room using a CAS-1200
robot (Corbett Research, Inc.) with 0.1 μL accuracy, liquid level sensing, and filtered pipette
tips. Real-time PCR was performed using an Opticon 2 unit (MJ Research, Inc.) and universal
cycle conditions.
RNase protection assay
RPAs were performed using the mirVana miRNA detection kit in accordance with the
manufacturer’s instructions (Ambion). 32P-labeled RNA probes were generated from DNA
templates corresponding to the miRNA target sequence using the mirVana miRNA probe
construction kit (Ambion) according to the manufacturer’s instructions.
BHRF1-3 miRNA or anti-miRNA transfection
Chemically modified oligonucleotides corresponding to the antisense to the BHRF1-3 miRNA
target sequence (BHRF1-3 anti-miR), the BHRF1-3 pre-miR miRNA precursor, scrambled
sequence, and a negative control anti-miR inhibitor were obtained from Ambion.
Oligonucleotides were delivered using the Amaxa nucleofection technology (Amaxa)
according to the manufacturer’s protocols.
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CXCL-11/I-TAC protein levels in cell culture conditioned medium were determined with the
Quantikine human CXCL-11/I-TAC ELISA kit (R&D Systems, Inc.) as per the manufacturer’s
instructions.
Results
To determine the expression pattern of EBV miRNAs in type I and III EBV-related lymphomas,
and to investigate their role in EBV pathogenesis, we initially used two BL early-passage cell
lines (BL-5 and BL-8) derived from primary tumors that carry the typical t8:14 chromosomal
translocation (Fig. 1A; ref. 13). Serially passaged primary cultures evolved from single-cell
suspension (BL-5) to macroscopic clumps (BL-5R), indicating a drift to lymphoblastoid
phenotype (Fig. 1B). The expression of viral-encoding proteins, EBNA3C, EBNA2, and
LMP-1, is associated with the lymphoblastoid phenotype (11,12). We therefore assessed the
transcription of these mRNAs in BL-5 and its lymphoblastoid derivative BL-5R by RT-PCR.
Although cultured BL-5 cells contained some detectable EBNA2 and EBNA3C transcripts, the
BL-5R cells, by comparison, expressed higher levels of EBNA2 and EBNA3C (Fig. 1C).
Consistent with its role in the lymphoblastoid phenotype, LMP-1 was exclusively expressed
in BL-5R cells (Fig. 1C) and LMP-1 protein expression was confirmed by Western blot (data
not shown).
Small RNAs (<200 nucleotides) were purified from BL-5, BL-8, and BL-5R cells and EBV
miRNA levels were determined by RPA. We observed elevated levels of BART2 miRNA in
the parental type I BL-5 cells and a marked expression of BHRF1-3 miRNA (and concomitantly
low levels of BART2 miRNA) in BL-5R cells (Fig. 2A, lanes 2 and 3). The early-passage type
I BL-8 cells also expressed high levels of BART2 miRNA, but BHRF1-3 miRNA was not
detectable in these cells (Fig. 2A, lane 1). This finding was in agreement with recently published
data on long-term established EBV+ cell lines that showed an increased level of BHRF1
miRNAs in type III latency cell lines (8).
We also analyzed viral miRNAs from an EBV+ primary DLBCL-1 biopsy. RPA analysis
revealed high levels of both BART2 and BHRF1-3 miRNAs in this tumor (Fig. 2A, lane 4),
but neither miRNA was detectable in its EBV− DLBCL counterpart (DLBCL-4; Fig. 2A, lane
5).
To verify the differential expression of the BHRF1-3 and BART2 miRNAs by another method,
we used real-time QPCR. Primers specific for the BHRF1-3, BART1, and BART2 pre-
miRNAs were designed. As control for RNA isolation, we used published primers against pre-
miRNAs for cellular miRNAs, miR16, miR124, and miR219 (19,20). All quantitative analyses
were normalized to account for differences in cell number, RNA quality, and reverse
transcription efficiency (17,18). We used U6 as the common denominator for these studies
because it was the most abundant RNA, normally distributed and the least variable RNA in
our target set (data not shown). Control experiments were done to discount mRNA or DNA
contamination of miRNA QPCR amplification (data not shown). The miRNA QPCR
confirmed the marked induction (~21-fold) of BHRF1-3 pre-miRNA in BL-5R cells relative
to BL-5 cells. BART pre-miRNAs did not show marked differences between BL-5 and BL-5R
(<2-fold) compared with BHRF1-3 pre-miRNA in the QPCR assay (Fig. 2B). In contrast to
the viral pre-miRNAs, none of the three cellular pre-miRNAs showed a pattern that correlated
with EBV status, indicating that specific viral miRNA regulation rather than global defects in
miRNA processing accounts for the pattern of viral miRNA levels. We also analyzed several
well-characterized PEL cell lines, wherein EBV assumes a tight latency I phenotype based on
latent EBV mRNA splicing patterns (18). BART1, BART2, and, to a lesser degree, BHRF1-3
pre-miRNAs were detectable in the EBV+ PEL cell lines BC-1 and JSC-1, but not in the
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EBV− BCBL-1 and BC-3 cell lines, and the expression levels were comparable with the latency
I BL-5 cells (data not shown).
As all prior studies were conducted entirely in long-term culture adopted cell lines, we assessed
the expression of EBV miRNAs in primary B-cell lymphomas classically associated with EBV.
Endemic-type pediatric BLs from an area of high incidence and DLBCLs from HIV+ patients
were confirmed to be EBV+ by in situ analysis of constitutively expressed EBV-encoded small
RNAs (EBER; Fig. 3A) and by RT-PCR of EBV-encoded mRNAs (data not shown). As a
control, an EBV (EBER)-negative DLBCL (DLBCL-4) was used in these analyses (Fig. 3A).
Each of the EBV+ DLBCLs expressed high levels of LMP-1 (Fig. 3B), confirming that they
are associated with type III EBV latency pattern. We also analyzed a primary EBV+ PEL
specimen (PELmo1) as well as the established EBV+ PEL line (BC-1). RPA analysis showed
that, as was observed in the EBV-associated BL lines (BL-5 and BL-8), endemic-type BLs
(BL-1, BL-2, BL-3, BL-4, and BL-6) also expressed predominantly BART2 miRNA (Fig.
3C, lanes 2, 3, 4, 5, and 7), whereas the EBV+ DLBCLs (DLBCL-1, DLBCL-2, and DLBCL-3)
expressed both BART2 and BHRF1-3 miRNAs at high levels (Fig. 3C, lanes 1, 6, 9, 11, and
12). The established PEL line and the primary PEL specimen both expressed predominantly
BART2 miRNAs (Fig. 3C, lanes 14 and 15), consistent with the reported type I EBV latency
transcription pattern in PEL. In EBV− controls (DLBCL-4 and BJAB), expression of both viral
miRNAs was not detected (Fig. 3C, lanes 8, 10, and 13). Therefore, as in the type I latency
cell line (e.g., BL-5), both EBV-associated primary BLs and PELs express high levels of
BART2 miRNA, whereas the expression of BHRF1-3 miRNA is markedly elevated in the type
III latency cell line (BL-5R) as well as in primary EBV+ AIDS-related DLBCLs. The types of
primary lymphomas and cell lines analyzed and their expression pattern of EBV miRNA are
summarized in Table 1.
The IFN-inducible T-cell attracting chemokine CXCL-11/I-TAC is one of three CC
chemokines, including CXCL-9/Mig and CXCL-10/IP-10, that bind to and activate the
chemokine receptor CXCR3, which is predominantly expressed on T cells (21,22). Although
these cytokines are functionally redundant, CXCL-11/I-TAC is by several orders of magnitude
the most potent T-cell chemo-attractant (21). Based on published in silico analysis, the 3′-UTR
of CXCL-11/I-TAC contains a sequence that is 100% complimentary to the BHRF1-3 miRNA
sequence and therefore constitutes a putative BHRF1-3 miRNA target (7). Because of
significantly differing BHRF1-3 miRNA levels, we hypothesized that CXCL-11/I-TAC might
also be differentially expressed in BL-5 and BL-5R. The basal level of CXCL-11/I-TAC
proteins secreted from culture supernatants of BL-5 and BL-5R was analyzed using ELISA.
BL-5 cells expressed higher levels of CXCL-11/I-TAC than BL-5R cells (Fig. 4A), suggesting
that the expression of CXCL-11/I-TAC in these cells inversely correlates with the expression
of EBV-encoded BHRF1-3 miRNA.
We investigated the effect of BHRF1-3 miRNA on its putative target, CXCL-11/I-TAC. First,
we studied the high BHRF1-3 miRNA BL-5R cell line. BL-5R cells were transfected with
increasing amounts of BHRF1-3 miRNA antisense oligonucleotide (BHRF1-3 anti-miR) at
~65% efficiency (Fig. 4B, top) and the CXCL-11/I-TAC level was assessed by RT-PCR. By
competing the BHRF1-3 miRNA targeting sequence with its antisense RNA oligonucleotide,
we repeatedly elicited basal induction of CXCL-11/I-TAC expression in BL-5R (Fig. 4B,
bottom, lanes 6–9). Control transfections with a scrambled RNA oligonucleotide (Fig. 4B,
bottom, lanes 2–5), as well as mock transfection (Fig. 4B, bottom, lane 1), showed no
modulation of CXCL-11/I-TAC expression. This result indicates that BHRF1-3 miRNA
antisense competes out BHRF1-3 miRNA and reverses its repressive effect on CXCL-11/I-
TAC expression. We also analyzed the expression of another chemokine, CXCL-7, in the same
set of experiments. RT-PCR showed that CXCL-7 mRNA level was not modulated by
transfection of either BHRF1-3 anti-miR or scrambled oligonucleotides (Fig. 4B, bottom),
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which indicates that the effect of BHRF1-3 miRNA on CXCL-11/I-TAC expression is specific.
Similarly, CXCL-11/I-TAC expression was markedly induced in the low BHRF1-3 miRNA
BL-5 cells transfected with BHRF1-3 anti-miR, and we also observed a much greater induction
of CXCL-11/I-TAC expression in BL-5 cells dually treated with both the antisense oligo of
BHRF1-3 miRNA and IFN-γ (data not shown). This showed that expression of CXCL-11/I-
TAC is suppressed by the EBV-encoded BHRF1-3 miRNA.
We further examined the direct effect of BHRF1-3 miRNA on CXCL-11/I-TAC expression.
CXCL-11/I-TAC was stimulated to a higher level in BL-5 cells when transfected with 100 nmol/
L BHRF1-3 anti-miR and induced with 1,000 units/mL IFN-γ (Fig. 4C, left and right, lanes
2–5). Cells were then transfected with increasing amounts of BHRF1-3 miRNA sense oligos
(Fig. 4C, left and right, lanes 3–5) and analyzed for CXCL-11/I-TAC by RT-PCR (Fig. 4C,
left) and ELISA (Fig. 4C, right). We observed a significant reduction of CXCL-11/I-TAC at
both mRNA and protein levels when cells were transfected with BHRF1-3 miRNA. This result
further shows that CXCL-11/I-TAC expression is suppressed by EBV miRNA BHRF1-3,
suggesting that cellular chemokines can be targeted by the viral miRNA.
Discussion
Following primary EBV infection, B cells undergo blast transformation during which they
express the full spectrum of EBV genes (latency III program; refs. 11,12). Presumably, to evade
host viral immune defenses, the cells later adopt a latency I program, in which EBV gene
expression is restricted to the relatively nonimmunogenic EBNA1 protein, the BamHI
transcripts including the BART miRNAs, and the noncoding EBER transcripts. It is thought
that BL arises from a B-cell subset in which EBV naturally adopts a tight latency I program or
that a clone with limited antigen expression is selected from an EBV-transformed latency III
progenitor pool (23). EBV latency III lymphomas typically arise in immunodeficient patients,
such as those infected with HIV, or following pharmacologic immunosuppression after organ
transplantation or they arise during in vitro culture of latency type I cells, which underscores
the importance of a robust immunosurveillance system to counter the expression of EBV genes
(23,24).
Although there are distinct forms of EBV latency types in established cell lines, the clinical
scenario is often quite different. Clinical specimens from patients with the diagnosis of BL
have been found to express a heterogeneous latency program (25–27). The heterogeneity of
EBV latency patterns in clinical specimens may be due to variant EBV clones, the
establishment of immunoprivileged sites in the tumor microenvironment, and the selection of
a clone from a type III progenitor pool (23,28). It may also be part of an immune evasion
strategy that includes EBV-mediated regulation of antigen processing and presentation and the
down-modulation of the cytotoxic T-cell (CTL) cytokine networks (29). It will be important
to study the biology of these primary EBV+ lymphomas to advance diagnosis and treatment.
The identification of virus-encoded miRNAs has generated new insights on virus
transformation and immune evasion. Sullivan et al. (9) showed that SV40-encoded miRNAs
target early viral mRNAs for cleavage, thus reducing the expression of viral tumor antigens,
CTL recognition, and cytolysis. Recently, Samols et al. (30) identified thrombospondin 1, a
strong tumor suppressor and anti-angiogenic factor, as a potential target for HHV-8–encoded
miRNAs, and Lo et al. (31) reported modulation of LMP-1 protein expression by EBV-encoded
BART miRNAs, highlighting the role of viral miRNAs in regulating viral pathogenesis.
We analyzed for the first time a variety of primary unmanipulated EBV-associated lymphomas
(rather than established cell lines) that are representative of the major forms that occur in
immunocompromised patients. Primary BLs expressed high levels of BART2 miRNA, which
Xia et al. Page 6













was expected based on the ubiquitous, high-level transcription across the BamHI locus in all
EBV+ tumors (32–34). In contrast, a lymphoblastoid derivative of a BL line derived from an
AIDS patient as well as AIDS-related DLBCLs expressed high levels of BHRF1-3 miRNA.
The expression pattern of these two EBV miRNAs correlated with that previously seen in long-
term cultured cell lines (8). An induced expression of BHRF1 miRNAs and a putative cleavage
residue have recently been reported in EBV+ AKATA cells induced from type I latency to type
III latency, indicating that the high level of BHRF1 miRNAs is a characteristic of EBV latency
III infection (35). It is interesting to note that BHRF1-3 miRNA was low or absent in AIDS-
related BL. These tumors typically occur in relatively immunocompetent patients compared
with EBV+ DLBCL, which arise in patients with more advanced immunodeficiency (36). In
contrast, EBV-associated large cell variants may exert a previously unknown
immunosuppressive effect via modulation of cellular chemokines. Therefore, we hypothesize
that one of the activities of EBV BHRF1-3 miRNA is the regulation of host cell immune
function. This article establishes that EBV miRNAs are readily detectable in primary
unmanipulated lymphomas associated with the virus. It is also likely that BHRF1-3 and other
EBV miRNAs have additional complementary cellular targets.
Two recent reports have shown a potent antitumor activity for the IFN-inducible T-cell
attracting chemokine (CXCL-11/I-TAC) in laboratory animals. However, there is a paucity of
studies on the expression of CXCL-11/I-TAC expression in clinical specimens (37,38). We
have identified EBV BHRF1-3 miRNA, which is 100% identical to its target sequence in the
3′-UTR of CXCL-11/I-TAC mRNA, as a potential effector in the modulation of CTL cytokine
networks (7). We show that CXCL-11/I-TAC mRNA and protein levels inversely correlate
with BHRF1-3 miRNA expression levels. Changes in BHRF1-3 miRNA levels in a pair of
isogenic type I/III BL cell lines were inversely correlated with CXCL-11/I-TAC levels.
Furthermore, antisense delivery of the BHRF1-3 miRNA could relieve BHRF1-3 miRNA
repression of CXCL-11/I-TAC. Therefore, the activity of BHRF1-3 miRNA and other virally
encoded miRNAs may have far-reaching implications in cancer immunosurveillance.
Alternatively, antisense delivery of BHRF1-3 miRNA may represent a targeted
immunotherapeutic tool that can be directed toward enhancing immunosurveillance of EBV-
related tumors.
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Cytogenetic and morphologic analysis of BL lines and differential expression of EBV genes
in latency type I and III BL lines. A, cytogenetic analysis of BL lines BL-5 and BL-8 reveals
the characteristic t8:14 c-MYC translocation. Arrows point to translocated chromosomes. B,
bright-field photomicrograph of BL-5 and BL-5R cells in culture. Magnification, ×100. BL-5
cells grow as a single-cell suspension, whereas BL-5R cells grow as macroscopic clumps,
characteristic of LCLs. C, RT-PCR analysis of EBV-encoded EBNA3C, EBNA2, and LMP-1
mRNA levels in BL-5 and BL-5R cells. β-Actin mRNA level was analyzed as loading control.
Agarose gels were exposed under UV light in a Bio-Rad Gel Doc 2000 imager and inverted
images of DNA bands captured.
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Differential expression of BHRF1-3 and BART2 miRNAs in BL cell lines. A, RPA analysis
of BHRF1-3 and BART2 miRNA expression in BL lines BL-8 and BL-5, a lymphoblastoid
derivative BL-5R, an EBV+ DLBCL-1(+), and an EBV− DLBCL-4(−). Expression of a cellular
miRNA, miR16, was analyzed as loading control. B, real-time QPCR analysis of EBV miRNA
expression in BL-5 and BL-5R cells. Bars, relative level of miRNAs in percentage to U6 RNA
on the vertical axis on a logarithmic scale. Expression of EBV miRNAs (BHRF1-3, BART1,
and BART2) and expression of cellular miRNAs (miR16, miR124, and miR219) were
analyzed.
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Differential expression of BHRF1-3 and BART2 miRNAs in primary unmanipulated clinical
specimens. A, representative immunohistochemical analysis in primary unmanipulated clinical
specimens. Endemic BLs (BL-1, BL-2, and BL-3) and primary DLBCLs (DLBCL-1 and
DLBCL-4) were stained with H&E (top row) or stained for EBER1 (bottom row). Positive
staining to EBV/EBER is visualized as dark blue spots. (−), EBV negative; (+), EBV positive.
B, Western blot of LMP-1 protein in primary DLBCLs. EBV+ DLBCL-1, DLBCL-2, and
DLBCL-3 were probed with specific antibody to LMP-1. An EBV− BL line, BJAB, was used
as a negative control, and the same membrane was also probed with β-tubulin for a loading
control. C, RPA analysis of BHRF1-3 and BART2 miRNA expression in primary EBV+ BLs
(BL-1, BL-2, BL-3, BL-4, and BL-6), EBV+ primary DLBCLs (DLBCL-1, DLBCL-2, and
DLBCL-3), a primary EBV+ PEL specimen (PELmo1), and an established EBV+ PEL line
(BC-1). EBV− DLBCL-4 and BJAB were also analyzed as negative controls, and miR16 as a
loading control.
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Differential expression and modulation of putative BHRF1-3 miRNA target CXCL-11/I-TAC.
A, ELISA analysis of basal level expression of CXCL-11/I-TAC proteins secreted from culture
supernatants of BL-5 and BL-5R. B, RT-PCR analysis of CXCL-11/I-TAC mRNA levels in
BL-5R cells following BHRF1-3 miRNA antisense transfection. Top, green fluorescent protein
(GFP) control to determine transfection efficiency; bottom, mRNA level of CXCL-11/I-TAC
following BHRF1-3 antisense transfection in BL-5R cells. BL-5R cells were transfected with
RNA oligonucleotides at the following dosages: control transfections with no oligo (lane 1);
transfection with a scrambled RNA oligo at 0.25 μmol/L for 8 h (lane 2), 1.25 μmol/L for 8 h
(lane 3), 0.25 μmol/L for 16 h (lane 4), and 1.25 μmol/L for 16 h (lane 5); and transfection
with anti-BHRF1-3 miRNA oligo at 0.25 μmol/L for 8 h (lane 6), 1.25 μmol/L for 8 h (lane
7), 0.25 μmol/L for 16 h (lane 8), and 1.25 μmol/L for 16 h (lane 9). CXCL-11/I-TAC,
CXCL-7, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA levels in
transfected cells were also analyzed by RT-PCR. PCR products were visualized under UV in
a Bio-Rad Gel Doc 2000 imager and inverted images of DNA bands were captured. C, effect
of BHRF1-3 miRNA on induced CXCL-11/I-TAC. BL-5 cells were transfected with 100 nmol/
L BHRF1-3 anti-miR and treated with 1,000 units/mL IFN-γ (lanes 2–5) and then transfected
with BHRF1-3 miRNA sense oligos (lane 2, 0 nmol/L; lane 3, 10 nmol/L; lane 4, 30 nmol/L;
lane 5, 100 nmol/L). CXCL-11/I-TAC and β-actin mRNA levels in transfected cells were then
analyzed by RT-PCR (left) and CXCL-11/I-TAC protein level was analyzed by ELISA
(right). Agarose gels were exposed under UV in a Bio-Rad Gel Doc 2000 imager and inverted
images of DNA bands captured.
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Table 1
EBV miRNA expression in primary lymphomas and cell lines
BART2 BHRF1-3
EBV+
 Early-passage BL lines BL-5 High Low
BL-8 High Low





 Type III derivative line BL-5R Low High
 Primary AIDS-related DLBCLs DLBCL-1 High High
DLBCL-2 High High
DLBCL-3 High High
 PELs BC-1 High Low
JSC-1 High Low
PELmo1 (primary) High Low
EBV−
 BL line BJAB None None
 Primary AIDS-related DLBCL DLBCL-4 None None
 PELs BCBL-1 None None
BC-3 None None
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